Cargando…
1101. Implementing a Beta-Lactam Therapeutic Drug Monitoring Program: Experience from a Large Academic Medical Center
BACKGROUND: Beta-lactams (BL) are the cornerstone of antimicrobial treatment for infections. Beta-lactam therapeutic drug monitoring (BL-TDM) optimizes drug concentrations to ensure maximal efficacy and minimal toxicity. The goals of this study were to describe the implementation process of a BL-TDM...
Autores principales: | Veena, Venugopalan, Hamza, Malva, Santevecchi, Barbara A, DeSear, Kathryn, Cherabuddi, Kartikeya, Peloquin, Charles A, Al-Shaer, Mohammad H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644826/ http://dx.doi.org/10.1093/ofid/ofab466.1295 |
Ejemplares similares
-
Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022) -
1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020) -
1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021) -
Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023) -
Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach
por: Maguigan, Kelly L., et al.
Publicado: (2021)